Chemistryof the nextnervous system.
We are a Swiss pharmaceutical research group designing, characterising and supplying API intermediates for central-nervous-system stimulants — from phenethylamine scaffolds to modafinil-class eugeroics.
A newcomer, engineered by veterans.
NewGenPharma was founded in 2023 in Zug by a coalition of medicinal chemists, process engineers, and clinical scientists whose combined résumé spans three decades of API development at tier-one Swiss and German houses. The group is young; the hands are not.
Focused on the central nervous system.
We concentrate our discovery on stimulants and cognition-modulating scaffolds — phenethylamines, tropane analogs, eugeroic modafinilines and next-generation aminoindanes — with an operational commitment to reproducible, scalable API intermediates.
Serving the intermediates market with rigor.
Our commercial spine is the API-intermediates market. Every gram we ship carries a full CoA, ICH-Q3A/D residual solvent profile, and DMF-ready documentation. Precision is not a marketing word; it is the deliverable.
NGP-107
phenethylamine class
A next-generation, selective norepinephrine-dopamine releaser optimised for lower cardiovascular liability. Currently in preclinical safety-pharmacology with a partner CRO in Allschwil.
See full pipeline